The abstract is read at the publisher; the summary is JClub's.
Tazemetostat (Tazverik) was withdrawn after SYMPHONY-1 showed hematologic second primary malignancies in 5.7% of treated patients versus none in controls.
- Why it matters: The result highlights a potential target-driven risk of EZH2 inhibition, since EZH2 can act as both oncogene and tumor suppressor depending on context.
- What they did: The confirmatory phase Ib/III SYMPHONY-1 trial compared treated versus control arms and reported hematologic second primary malignancies, with MDS and AML most frequently observed.
- The result: The safety signal implies EZH2 inhibition may phenocopy loss-of-function states linked to myeloid neoplasia, motivating updated preclinical testing, trial design, and pharmacovigilance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.